Harvard Bioscience (HBIO) Fundamental Analysis: Revenue, Earnings & Valuation

1.57 / 10

Underperform

Fundamental rating is Underperform, with a 1.6/10 score. Cash‑flow ratios (operating cash flow to liabilities and revenue) are positive, but profit‑to‑market and net‑income‑to‑revenue metrics are weak. Overall fundamentals are subpar, suggesting selective exposure.

Analysis Checks(2/10)

Revenue-MV

Value1.19

Score1/3

Weight18.80%

1M Return-2.72%

Net cash flow from operating activities / Operating revenue (%)

Value7.77

Score2/3

Weight-6.77%

1M Return0.90%

Profit-MV

Value0.66

Score1/3

Weight21.32%

1M Return-2.85%

Net income-Revenue

Value-0.04

Score1/3

Weight19.08%

1M Return-2.58%

Net profit margin (%)

Value-65.51

Score1/3

Weight-1.73%

1M Return0.24%

Cash-UP

Value-0.15

Score1/3

Weight41.67%

1M Return-6.49%

Net cash flow from operating activities / Total liabilities (%)

Value0.10

Score2/3

Weight-5.78%

1M Return0.68%

EBIT / Total operating revenue (%)

Value-60.62

Score1/3

Weight4.16%

1M Return-0.58%

Asset-MV

Value-0.55

Score1/3

Weight10.98%

1M Return-2.84%

Net profit / Total operating revenue (%)

Value-65.51

Score1/3

Weight-1.73%

1M Return0.24%

Is HBIO fundamentally strong?

HBIO scores 1.57/10 on fundamentals and holds a Premium valuation at present. Backed by its -147.13% ROE, -65.51% net margin, -0.40 P/E ratio, 1.66 P/B ratio, and -357.14% earnings growth, these metrics solidify its Underperform investment rating.